The U.S. Food and Drug Administration has approved three PD-1 inhibitors (nivolumab, pembrolizumab and cemiplimab) and two PD-L1 inhibitors (atezolizumab and durvalumab) for the treatment of NSCLC with different stages (3–6). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.